Akumen's bacteria CCFM1087 capable of relieving obesity and application thereof

Abstract

The application discloses an Akkermansia strain CCFM1087 capable of relieving obesity and an application thereof, and belongs to the field of microorganisms. The Akkermansia strain CCFM1087 provided by the application can relieve obesity induced by a high-fat diet, slow down the weight gain speed, reduce the fat content of the body, inhibit the lipase activity, reduce the TC, TG, AST, ALT and LDL-C content in serum, up-regulate the HDL-C content, reduce the liver inflammation damage and oxidative stress, relieve chronic low-grade inflammation, regulate the oral glucose tolerance homeostasis of the body, regulate the intestinal flora of the body, reverse the intestinal flora disorder caused by the high-fat diet, and can also improve the conversion rate and bioavailability of quercetin. The Akkermansia strain CCFM1087 is used for preparing a probiotic product, can effectively relieve obesity induced by a high-fat diet in multiple aspects, and has a wide application prospect.

Description

Technical Field

[0001] This invention relates to an Akkermansia strain CCFM1087 that can alleviate obesity and its applications, belonging to the field of microbiology. Background Technology

[0002] In recent years, with changes in dietary structure and lifestyle, the incidence of overweight and obesity has been rising. Obesity is a chronic metabolic disease characterized by excessive fat accumulation and energy metabolism imbalance. It is often accompanied by glucose and lipid metabolism disorders, chronic low-grade inflammation, oxidative stress, and hepatic lipid deposition, and can further increase the risk of insulin resistance, type 2 diabetes, metabolic dysfunction-related fatty liver disease, and cardiovascular disease. Therefore, developing safe, effective, and long-term suitable obesity intervention methods is of great significance.

[0003] The gut microbiota plays a crucial role in dietary component metabolism, intestinal barrier maintenance, immune inflammation regulation, and host energy metabolism. Abnormalities in its composition and metabolic function are closely related to the development and progression of obesity. Regulating the gut microbiota and its metabolites through functional microorganisms has become an important research direction for intervening in obesity and related metabolic disorders. Among these, *Akkermansia myxophilus* (…) Akkermansia muciniphila Akkermansia is a gut bacterium with potential probiotic effects. Related safety studies showed no significant toxic or adverse reactions during a 90-day toxicity test. However, Akkermansia exhibits highly strain-specific biological functions; strains isolated from different sources and individuals show significant differences in regulating host metabolism. Currently, commercially available strains are limited, and the existing standard strain ATCC BAA-835's efficacy in weight loss, improving glucose and lipid metabolism, alleviating inflammation, and regulating gut microbiota dysbiosis still cannot fully meet the needs of clinical and functional food development. Therefore, screening new strains with more comprehensive functions and superior overall efficacy from the gut microbiota of natural populations is of significant practical necessity and urgency.

[0004] On the other hand, dietary flavonoids have shown promising potential in the intervention of obesity-related metabolic disorders. Both quercetin and senna-2, quercetin are natural flavonoids with diverse biological activities and high development and utilization value in functional foods and related health products. However, due to factors such as molecular structure and physicochemical properties, quercetin has poor water solubility, and its oral absolute bioavailability is typically only 1%–5%. Senna-2, quercetin also faces problems such as low intestinal conversion efficiency, insufficient generation of active metabolites, and limited absorbable forms, severely limiting its efficacy. Gut microorganisms play a crucial role in the biotransformation of dietary polyphenols, and the production of microbial metabolites such as protocatechuic acid and senna-2, quercetin is closely related to their in vivo biological effects. However, there is still a lack of sufficient research and effective strain resources to utilize specific functional probiotics to synergize with gut microbiota, promote the intestinal conversion of the aforementioned flavonoids, and enhance the bioavailability of their active metabolites.

[0005] Therefore, there is an urgent need to screen multifunctional strains that possess excellent anti-obesity efficacy, regulate gut microbiota, and synergistically promote the bioavailability of dietary bioactive molecules, so as to provide a new technical basis for microecological intervention in obesity and related metabolic diseases. Summary of the Invention

[0006] The first objective of this invention is to provide a strain of Akkermansia ( Akkermansia muciniphila CCFM1087 was deposited on February 4, 2026, at the Guangdong Provincial Center for Microbial Culture Collection, located at the Guangdong Institute of Microbiology, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC No: 67807.

[0007] The present invention also provides a metagene of the aforementioned Akkermansia CCFM1087.

[0008] In one embodiment, the metabiotic includes inactivated cells of Akkermansia CCFM1087, metabolites of Akkermansia CCFM1087, and / or cell lysis components of Akkermansia CCFM1087.

[0009] In one embodiment, the method for preparing inactivated cells of Akkermansia CCFM1087 includes: culturing Akkermansia CCFM1087 in a culture medium to a cell count ≥1×10⁻⁶. 9 CFU / mL, treated at 65-75℃ for 20-40 min.

[0010] In one embodiment, the culture medium contains quercetin and / or senna-2-glucosinolate.

[0011] In one embodiment, the culture medium contains quercetin.

[0012] In one embodiment, the culture medium contains senna-2-glucosinolates.

[0013] A second object of the present invention is to provide a composition containing the Akkermansia CCFM1087 and / or its postbiotic.

[0014] In one embodiment, the composition further contains quercetin and / or senna-2-glucosinolate.

[0015] In one embodiment, the composition contains (based on the bacterial cell count before inactivation) ≥5 × 10⁻⁶ 9 CFU / g or 5×10 9 Akkermansia CCFM1087 cells at CFU / mL.

[0016] In one embodiment, the composition is a microbial preparation, a functional food, a health product, or a drug.

[0017] In one embodiment, the microbial preparation is a solid or liquid preparation.

[0018] In one embodiment, the microbial preparation is obtained by drying a bacterial suspension containing Akkermansia CCFM1087, resulting in a pre-inactivation viable count ≥5 × 10⁻⁶. 9 CFU / g or 5×10 9 Powder with CFU / mL.

[0019] In one embodiment, the functional food can be prepared using conventional methods.

[0020] In one embodiment, the composition is a fermented food, including solid food, liquid food, or semi-solid food.

[0021] In one embodiment, the food is a beverage or snack containing the Akkermansia CCFM1087 or its postgenes.

[0022] In one embodiment, the fermented food includes dairy products, soy products, or fruit and vegetable products.

[0023] In one embodiment, the dairy products include fermented milk, flavored fermented milk, fermented milk beverages, cheese, milk-containing beverages, or milk powder; the soy products include soy milk or soy milk powder; and the fruit and vegetable products include fruit and vegetable products made from at least one of cabbage, white radish, cucumber, beet, yellow peach, or bayberry products.

[0024] In one embodiment, the drug further comprises a pharmaceutically acceptable carrier.

[0025] In one embodiment, the carrier includes one or more of the following commonly used in medicine: fillers, adhesives, wetting agents, disintegrants, lubricants, and flavoring agents.

[0026] In one embodiment, the dosage form of the drug is granules, capsules, tablets, pills, or oral liquid.

[0027] The present invention also provides the use of the Akkermansia CCFM1087 and / or the metabiotic in the preparation of medicaments for the prevention and / or treatment of obesity.

[0028] In one embodiment, the application includes treating obesity-related metabolic disorders.

[0029] In one embodiment, the metabolic disorder includes at least one of hyperlipidemia, impaired glucose tolerance, hepatic steatosis, and chronic low-grade inflammation.

[0030] In one implementation, the obesity is obesity induced by a high-fat diet.

[0031] The present invention also provides the use of the aforementioned Akkermansia CCFM1087 and / or the aforementioned metabiotic in the preparation of products for reducing body weight, reducing fat accumulation and / or inhibiting lipase activity.

[0032] The present invention also provides the use of the aforementioned Akkermansia CCFM1087 and / or the aforementioned metabiotic in the preparation of products that help regulate the gut microbiota.

[0033] In one embodiment, the product includes a medicine or health product.

[0034] In one embodiment, the regulation of gut microbiota includes increasing gut microbiota α diversity and / or decreasing the ratio of Firmicutes to Bacteroidetes.

[0035] The present invention also provides the use of the Akkermansia CCFM1087 in the preparation of products for promoting the intestinal conversion of quercetin and / or senna-2-glucosinolates and / or improving the bioavailability of their active metabolites.

[0036] In one embodiment, the application includes promoting the conversion of quercetin to one or more of protocatechuic acid, 3,4-dihydroxyphenylacetic acid, and isorhamnetin.

[0037] In one embodiment, the application includes promoting the conversion of senna-7-O-glucoside, senna-7-O-glucoside, and dihydrocaffeic acid into one or more of these.

[0038] In one embodiment, the application includes co-fermenting the Akkermansia CCFM1087 with a substrate containing quercetin and / or senna under anaerobic conditions.

[0039] The beneficial effects of this invention are: The Akkermansia citrate strain CCFM1087 provided by this invention can improve the conversion rate of quercetin and senna-2-glucosinolates, as well as the bioavailability of quercetin in in vitro digestion. This strain and its post-biotic have the following functions: (1) It slowed down the weight gain caused by high-fat diet, reduced fat content, and reduced weight gain by 39.43% compared with the model group and weight loss by 23.32%, which was significantly better than the standard strain ATCC BAA-835. (2) Systemic improvement of metabolic disorders caused by obesity can reduce oral glucose tolerance (area under the curve by 20.83%), reduce serum total cholesterol, triglycerides and low-density lipoprotein cholesterol levels, increase high-density lipoprotein cholesterol levels, and significantly reduce liver damage markers ALT and AST levels, effectively alleviating liver inflammation and blood lipid abnormalities caused by high-fat diet. (3) It inhibits systemic chronic low-grade inflammation and oxidative stress, significantly downregulates serum pro-inflammatory factors and reduces the levels of IL-6, IL-1β and TNF-α in serum (with a reduction of 34%~38%), while reducing the level of malondialdehyde in the liver (65.42%) and increasing the activity of superoxide dismutase (27.09%), showing systemic anti-inflammatory and antioxidant effects; (4) Restore the α-diversity of gut microbiota caused by a high-fat diet, reduce the Firmicutes / Bacteroidetes ratio, and repair the dysbiosis; (5) Promotes the intestinal transformation of quercetin and significantly improves the generation and bioavailability of its active metabolites. In an in vitro simulated intestinal fermentation system, CCFM1087 increased the conversion rate of quercetin by 52.76%, and increased the yields of active metabolites protocatechuic acid, 3,4-dihydroxyphenylacetic acid and isorhamnetin by 46.56%, 52.66% and 77.84%, respectively; the dialysability (simulated absorption rate) of the three metabolites increased by 25.94%, 43.56% and 26.42%, respectively. (6) Promotes the intestinal transformation of senna-7-O-glucoside, improves the yield and bioavailability of its active metabolites, increases the conversion rate of senna-7-O-glucoside by 57.51%, increases the yield of senna-7-O-glucoside, senna-7-O-glucoside, and dihydrocaffeic acid by 60.71%, 70.42%, and 69.37%, respectively, and increases the dialysis rate by 48.81%, 68.84%, and 67.41%, respectively. It has shown outstanding performance in enhancing the intestinal utilization of senna-7-O-glucoside active molecules. (7) It has the effect of inhibiting lipase activity. After co-fermentation with fecal bacteria, the inhibition rate of lipase activity increased by 77.14% compared with the fermentation control group and by 69.30% compared with the standard strain BAA-835, suggesting that it can reduce fat absorption by inhibiting the dietary fat hydrolysis pathway, providing multiple mechanisms for weight management.

[0040] Preservation of biological materials Akkermania ( Akkermansia muciniphila (CCFM1087, categorized as follows) Akkermansia muciniphila It was deposited on February 4, 2026 at the Guangdong Provincial Center for Microbial Culture Collection, located at the Guangdong Institute of Microbiology, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC No: 67807. Attached Figure Description

[0041] Figure 1 The effect of Akkermansia CCFM1087 on mouse body weight and weight gain; Figure 2 The effect of Akkermansia CCFM1087 on oral glucose tolerance in mice; Figure 3 The effects of Akkermansia CCFM1087 on serum TC, TG, ALT, AST, LDL-C, and HDL-C levels in mice; Figure 4 The effect of Akkermansia CCFM1087 on the levels of inflammatory cytokines IL-6, IL-1β, and TNF-α in mouse serum; Figure 5 The effects of Akkermansia CCFM1087 on liver tissue weight, epididymal adipose tissue weight, perirenal adipose tissue weight, and adipose coefficient in mice; Figure 6 The effects of Akkermansia CCFM1087 on the levels of oxidative stress markers MDA (malondialdehyde) and SOD (superoxide dismutase) in mouse liver tissue; Figure 7 The effect of Akkermansia CCFM1087 on the α-diversity of the intestinal flora in mice; Figure 8 The effect of Akkermansia CCFM1087 on the ratio of Firmicutes to Bacteroidetes in the intestinal flora of mice; Figure 9 This study investigated the inhibitory effect of Akkermansia CCFM1087 on lipase activity.

[0042] Note: The symbols above the bars indicate the significance level of the data. * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.0001 (compared with the model group). Detailed Implementation

[0043] The culture media involved in the following examples are as follows: BHI medium (per L contains): 17.5 g ox heart extract; 10 g tryptone; 5.0 g sodium chloride; 2.0 g glucose; 2.5 g disodium hydrogen phosphate; 1 mL Tween 80; 1.0 g L-cysteine ​​hydrochloride; 2.5 g mucin; adjust pH to 7.4 ± 0.2; bring volume to 1 L. Autoclave at 121℃ for 15 min.

[0044] BHI solid medium: Add 2% agar powder to BHI liquid medium.

[0045] Example 1: Screening of Akkermansia CCFM1087 and preparation of bacterial suspension (1) Take 1g of fecal sample from an adult male in Huadian City, Jilin Province, dilute it serially, spread it on BHI medium, and incubate it in an anaerobic incubator at 37°C for 72 h.

[0046] (2) After culturing, based on the color, size, edge shape, etc. of the colonies, use an inoculation loop to pick up the colonies and streak them for purification.

[0047] (3) The obtained colonies were subjected to Gram staining and catalase analysis.

[0048] (4) Retain Gram-negative bacilli and catalase-negative bacteria.

[0049] (II) Molecular biological identification of Akkermansia (1) Single-strain genome extraction The Akkermansia strains screened in step (I) were cultured overnight; 1 mL of the overnight bacterial suspension was transferred to a 1.5 mL centrifuge tube, centrifuged at 10,000 rpm for 2 min, and the supernatant was discarded to obtain bacterial cells; the bacterial cells were washed with 1 mL of sterile water, centrifuged at 10,000 rpm for 2 min, and the supernatant was discarded to obtain bacterial cells; the bacterial cells were resuspended in 1 mL of sterile water for PCR identification. (2) 16S rDNA PCR (a) PCR reaction system of 20 μL bacterial 16S rDNA 10×Taq Mixture, 10 μL; bacterial suspension, 0.5 μL; primer 27F, 0.5 μL; primer 1492R, 0.5 μL; ddH2O, 8.5 μL.

[0050] (b) PCR conditions 95℃ 5min; 95℃ 30s; 55℃ 30s; 72℃ 2min; step 2-4 34×; 72℃ 10min; 12℃ 2min.

[0051] (c) Prepare a 1% agarose gel, then mix the PCR product with 10× loading buffer, load 2 μL, run at 120V for 30 min, and then perform gel imaging; (d) The obtained PCR products were sent to a professional sequencing company. The sequencing results were searched and compared with Genbank using BLAST. The strains identified as Akkermania were stored at -80℃.

[0052] (III) Whole genome sequencing The extracted whole genome was sent to a professional sequencing company, where the whole genome of the bacteria was sequenced using a second-generation sequencer. The obtained sequence results were searched and compared for similarity in Genbank using BLAST. The sequencing results identified it as belonging to Akkermania, named CCFM1087, and stored at -80℃ for later use.

[0053] (iv) Preparation of Akkermansia inactivated bacterial solution Akkermansia CCFM1087 and Akkermansia standard strain ATCC BAA-835 were inoculated into BHI solid medium and cultured in an anaerobic incubator at 37°C for 72 h to obtain single colonies. These single colonies were then inoculated into BHI liquid medium and cultured in an anaerobic incubator at 37°C for 48 h for activation. The activated bacterial culture (3 generations) was then inoculated into 1 L of BHI liquid medium at a 3% inoculation rate, shaken to mix, and cultured in an anaerobic incubator at 37°C for 48 h. After centrifugation at 8000g and 4°C for 15 min, the supernatant was discarded, and the cells were washed twice with sterile physiological saline. The cells were then centrifuged again under the same conditions, the supernatant was discarded, and the cells were resuspended in sterile physiological saline to obtain a bacterial concentration of 5 × 10⁻⁶. 9 The bacterial suspension of CFU / mL was pasteurized at 70℃ for 30 min and then used in animal experiments.

[0054] Example 2: Effect of Akkermansia CCFM1087 on weight gain in obese mice Twenty-four healthy male C57BL / 6J mice, aged 4 weeks, were randomly divided into four groups after one week of acclimatization: a healthy control group, a model group (high-fat diet-induced obesity model), an Akkermansia intervention group (CCFM1087), and an Akkermansia ATCC BAA-835 intervention group. The healthy control group and model group received 0.2 mL of physiological saline daily, while the Akkermansia CCFM1087 and ATCC BAA-835 intervention groups received 0.2 mL of a 5.0 × 10⁻⁶ bacterial concentration daily. 9CFU / mL of inactivated Akkermansia bacterial suspension. Experimental groups and treatment methods are shown in Table 1. The basal control diet was XTCON50J from Jiangsu Xietong Biotechnology Co., Ltd., with 10% fat energy supply, and the high-fat diet was XTFH60 from Jiangsu Xietong Biotechnology Co., Ltd., with 60% fat energy supply.

[0055] Table 1 Animal Experiment Grouping

[0056] During the twelve-week animal experiment, the weight of each mouse in each group was recorded weekly, and the trend of weight change in each group is as follows: Figure 1 As shown, the body weight of mice in the healthy control group, model group, and CCFM1087 intervention group all showed an increasing trend. The average initial body weight of mice in the healthy control group, model group, CCFM1087 intervention group, and ATCC BAA-835 intervention group were 18.82±0.11g, 18.89±0.70g, 18.25±1.02g, and 18.19±0.78g, respectively. There was no significant difference in the average initial body weight among the three groups (p>0.05). At the end of the experiment, the average body weight of the four groups of mice were 28.51±1.12g, 41.45±2.43g, 31.78±2.18g, and 35.43±3.06g, respectively. The average weight gains were 9.68±1.27g, 22.80±2.25g, 13.81±3.62g, and 17.24±2.16g, respectively. Compared with the model group, the average weight gains in the CCFM1087 intervention group and the ATCC BAA-835 intervention group were significantly different from those in the model group. Furthermore, compared to the model group, the CCFM1087 intervention group showed a 39.43% reduction in weight gain and a 23.32% reduction in body weight. The ATCC BAA-835 intervention group showed a 24.39% reduction in weight gain and a 14.52% reduction in body weight. This indicates that the CCFM1087 strain has a significant effect on controlling body weight gain, and its effect is superior to that of the standard strain ATCC BAA-835.

[0057] Example 3: Akkermansia CCFM1087 showed a good alleviating effect on oral glucose tolerance in high-fat induced obese mice. The grouping, modeling, and treatment methods for C57BL / 6J mice were the same as in Example 2. At week 10 of the animal experiment, the mice underwent an oral glucose tolerance test. Mice were fasted for 12 hours, with free access to water. A glucose solution was administered by gavage at a dose of 2 g / kg. Blood glucose levels were measured using a glucometer at 0, 15, 30, 60, 90, and 120 minutes after gavage, using tail-tip blood collection. Blood glucose curves were plotted, and the area under the glucose curve (AUC) was calculated using the trapezoidal method. The results of the oral glucose tolerance test are as follows: Figure 2 As shown, the blood glucose level of mice reached its peak 15 minutes after gavage administration of glucose solution. At this time, the average blood glucose levels of the healthy control group, model group, CCFM1087 intervention group, and ATCC BAA-835 intervention group were 12.24±1.88 mmol / L, 18.67±2.92 mmol / L, 18.04±3.38 mmol / L, and 15.96±3.27 mmol / L, respectively. After 15 minutes, the blood glucose level began to decline. The blood glucose level in the model group declined more slowly, and the blood glucose level of mice was still higher than the baseline level at the beginning of the experiment after 2 hours. Compared with the model group, the blood glucose levels of mice in the healthy control group and CCFM1087 group showed a faster decline, and the average blood glucose levels of mice in both groups returned to the baseline level after 2 hours. We further analyzed the area under the curve. The CCFM1087 intervention group and ATCC BAA-835 intervention group showed the highest blood glucose levels. The mean areas under the curve for the BAA-835 intervention group and the model group were 1319±138.3, 1453±249.5, and 1666±303.6, respectively. The CCFM1087 intervention group and the ATCC BAA-835 intervention group... Compared with the model group, the levels were significantly reduced by 20.83% and 12.78%, respectively. This indicates that the intervention of Akkermansia CCFM1087 significantly alleviated oral glucose tolerance disorder caused by a high-fat diet, and the effect was better than that of the standard strain ATCC BAA-835.

[0058] Example 4: Effects of Akkermansia CCFM1087 on serum TC, TG, HDL-C, LDL-C, AST, and ALT levels in high-fat diet-induced obese mice The grouping, modeling, and treatment methods for C57BL / 6J mice were the same as in Example 2, except that after 12 weeks of feeding, the mice were fasted for 12 hours, anesthetized with isoflurane, and blood was collected from the eyeballs. After standing at room temperature for 1 hour, the blood was centrifuged at 4°C and 3500 r / min for 15 minutes. The levels of TC, TG, HDL-C, LDL-C, AST, and ALT in the mouse serum were detected using a fully automated biochemical analyzer. The results are as follows: Figure 3As shown. Compared with the model group, the levels of TC (p<0.05), TG (p<0.001), LDL-C (p<0.0001), AST (p<0.05), and ALT (p<0.01) in the serum of mice after CCFM1087 intervention were significantly decreased, while HDL-C was significantly upregulated (p<0.0001). In the model group, the serum levels of TC, TG, HDL-C, LDL-C, ALT, and AST were 5.07±0.71 (mmol / L), 1.05±0.13 (mmol / L), 2.3±0.46, 0.91±0.18, 106.2±61.84, and 70.25±10.26 (U / L), respectively. After CCFM1087 intervention, the serum levels of TC, TG, HDL-C, LDL-C, ALT, and AST were 4.13±0.53 (mmol / L). The levels of TC, TG, LDL-C, ALT, and AST in the CCFM1087 group were 0.75±0.06 mmol / L, 3.39±0.12 mmol / L, 0.55±0.05 mmol / L, 33.10±4.20 U / L, and 54.03±6.33, respectively. Compared with the model group, the levels of TC, TG, LDL-C, ALT, and AST in the CCFM1087 group decreased by 18.54%, 28.57%, 39.56%, 68.83%, and 23.08%, respectively, while HDL-C increased by 47.39%. Compared with the model group, the levels of TC, TG, LDL-C, ALT, and AST in the ATCC BAA-835 intervention group decreased by 14.99%, 17.14%, 27.84%, 59.25%, and 18.83%, respectively, while HDL-C increased significantly by 25.74% after the intervention. This indicates that Akkermansia CCFM1087 can effectively alleviate liver inflammation caused by a high-fat diet and the potential harm to the blood caused by a high-fat diet, and the allergic effect is better than that of ATCC BAA-835.

[0059] Example 5: Akkermansia CCFM1087 reduced serum levels of inflammatory cytokines IL-6, IL-1β, and TNF-α in high-fat diet-induced obese mice. The grouping, modeling, and treatment methods for C57BL / 6J mice were the same as in Example 2. The levels of TNF-α, IL-6, and IL-β in mouse serum were measured using an ELISA kit (Shanghai Enzyme Linked Laboratory). The results are as follows: Figure 4As shown in the figure, the levels of TNF-α in mice in the healthy control group, model group, CCFM1087 intervention group, and ATCC BAA-835 intervention group were 50.99±11.75 pg / ml, 106.00±26.22 pg / ml, 69.46±17.25 pg / ml, and 74.89±9.01 pg / ml, respectively. Compared with the model group, the serum TNF-α levels in the CCFM1087 intervention group and ATCC BAA-835 intervention group decreased by 34.47% and 29.34%, respectively. The serum IL-6 levels in the four groups of mice were 47.92±10.29 pg / ml, 105.1±31.83 pg / ml, 65.90±16.90 pg / ml, and 72.63±7.48 pg / ml, respectively. Compared with the model group, the IL-6 levels in the CCFM1087 intervention group and the ATCC BAA-835 intervention group decreased by 37.20% and 30.89%, respectively. The serum IL-1β levels in the four groups of mice were 52.07±12.69 pg / ml, 94.19±25.34 pg / ml, 60.93±14.99 pg / ml, and 65.07±6.64 pg / ml, respectively. Compared with the model group, the serum IL-1β levels in the CCFM1087 intervention group and the ATCC BAA-835 intervention group were significantly downregulated by 35.31% and 30.92%, respectively. Compared with the model group, the levels of three inflammatory factors, TNF-α (p<0.01), IL-6 (p<0.05), and IL-1β (p<0.05), were significantly reduced in the CCFM1087 group mice, and the effect was better than that of the standard strain ATCC BAA-835. This indicates that CCFM1087 can significantly improve systemic chronic low-grade inflammation induced by a high-fat diet.

[0060] Example 6: Akkermansia CCFM1087 reduced liver, epididymal, and perirenal fat weight and fat coefficient in mice. The grouping, modeling, and treatment methods for C57BL / 6J mice were the same as in Example 2, except that at the end of the experiment, the mice were fasted for 12 hours but allowed free access to water. After anesthetizing the mice with isoflurane, blood was collected from the orbital cavity, and the mice were euthanized by cervical dislocation. Fresh liver tissue and epididymal adipose tissue were then dissected and immediately weighed, and the tissue weights were recorded. The results are as follows: Figure 5As shown, the liver tissue weights of mice in the healthy control group, model group, CCFM1087 intervention group, and ATCC BAA-835 intervention group were 0.86±0.11g, 1.21±0.20g, 0.80±0.07g, and 1.01±0.10g, respectively. Compared with the model group, the liver weights of mice in the CCFM1087 intervention group and the ATCC BAA-835 intervention group were significantly reduced by 33.88% and 16.52%, respectively, indicating that CCFM1087 effectively alleviated liver hypertrophy caused by a high-fat diet. The epididymal adipose tissue weights of the four groups of mice were 0.45±0.09g, 2.16±0.24g, 1.46±0.36g, and 1.56±0.15g, respectively. Compared with the model group, the epididymal adipose tissue weights of the CCFM1087 intervention group and the ATCC BAA-835 intervention group were significantly reduced by 32.41% and 27.77%, respectively, indicating that CCFM1087 effectively reduced the weight of the liver and epididymal adipose tissue in mice. The perirenal adipose tissue weights of the four groups of mice were 0.08±0.02g, 0.65±0.08g, 0.39±0.07g, and 0.53±0.07g, respectively. Compared with the model group, the perirenal adipose tissue weights of the CCFM1087 intervention group and the ATCC BAA-835 intervention group were significantly reduced by 40.00% and 18.46%, respectively. While reducing the weight of adipose tissue, the body fat index was also reduced accordingly. This indicates that CCFM1087 intervention can effectively alleviate liver hypertrophy caused by a high-fat diet, significantly reduce the body's adipose tissue content, alleviate obesity symptoms, and has a better effect than the Akkermansia standard strain ATCC BAA-835.

[0061] Example 7: Akkermansia citrate CCFM1087 can reduce the levels of SOD (superoxide dismutase) and MDA (malondialdehyde) in mouse liver, alleviating liver oxidative stress. The grouping, modeling, and treatment methods for C57BL / 6J mice were the same as in Example 2, except that at the end of the experiment, the mice were fasted but allowed free access to water for 12 hours. After anesthetizing the mice with isoflurane, blood was collected from their eyeballs, and the mice were euthanized by cervical dislocation. 50 mg of fresh liver tissue was taken from the dissection and placed in a 1.5 ml centrifuge tube. 450 μL of physiological saline and an appropriate amount of homogenate were added to the centrifuge tube. The homogenate was prepared using a high-throughput tissue homogenizer at 65 Hz for 40 seconds under ice bath conditions, with a 10-second delay. This process was repeated five times to prepare a 10% liver homogenate. After homogenate preparation, the liver homogenate supernatant was separated by centrifugation at 3500 r / min for 10 minutes at 4°C. The malondialdehyde and superoxide dismutase contents in the mouse liver tissue were measured using Nanjing Jiancheng MDA and SOD kits. The results are as follows: Figure 6As shown, the MDA content in the livers of mice in the healthy control group, model group, CCFM1087 intervention group, and ATCC BAA-835 intervention group were 0.59±0.15 nmol / mgprot, 2.14±0.35 nmol / mgprot, 0.74±0.18 nmol / mgprot, and 0.94±0.06 nmol / mgprot, respectively. Compared with the model group, the MDA content in the livers of mice in the CCFM1087 intervention group and ATCC BAA-835 intervention group was significantly reduced by 65.42% and 56.07%, respectively (p<0.0001). The SOD content in the livers of the four groups of mice were 93.71±5.12 U / mgprot, 76.70±6.09 U / mgprot, 97.48±20.85 U / mgprot, and 95.24±10.63 U / mgprot, respectively. Compared with the model group, the SOD content in the liver of CCFM1087 mice was significantly upregulated by 27.09% and 24.17% in the ATCC BAA-835 intervention group (P < 0.05). This indicates that CCFM1087 effectively alleviates the body's oxidative stress response, and its effect is superior to that of the standard strain ATCC BAA-835.

[0062] Example 8: Regulatory effect of Akkermansia CCFM1087 on mouse intestinal flora The grouping, modeling, and treatment methods for C57BL / 6J mice were the same as in Example 2. Mouse feces were collected, and total DNA was extracted from the colon contents of mice according to the instructions on the MP mouse fecal DNA extraction kit. The total DNA was used as a template for amplification, with primers 341F and 806R from the high-efficiency amplification region. The primer sequences were 341F: 5'-CCTAYGGGRBGCASCAG-3', and 806R: 5'-GGACTACNNGGGTATCTAAT-3'. The amplified product was approximately 465 bp in size. A 1.8% agarose gel was prepared for electrophoresis. The PCR amplified product was run on the gel, and the gel was cut according to the size of the target band. The target band was purified and recovered according to the gel recovery kit instructions. The DNA concentration was detected using a Nanojob nucleic acid analyzer. A library was constructed using the TruSeq Nano DNA LT Sample Preparation Kit and sequenced on an Illumina Miseq PE300 platform. The α-diversity of the bacterial community was characterized using the chao1 index, and the results are shown below. Figure 7 As shown, both Akkermansia CCFM1087 and ATCC BAA-835 significantly upregulated the α-diversity of the gut microbiota (P < 0.05), improving the species abundance of the gut microbiota. Furthermore, as... Figure 8As shown, intervention with Akkermansia CCFM1087 significantly reduced the proportion of Firmicutes and increased the proportion of Bacteroidetes in the gut, reversing the gut microbiota dysbiosis caused by obesity. In contrast, ATCC BAA-835 did not significantly affect the ratio of Bacteroidetes to Firmicutes in the gut microbiota. These results indicate that intervention with Akkermansia CCFM1087 can alleviate gut microbiota dysbiosis, possesses the ability to regulate the gut microbiota, and is more effective than the standard strain ATCC BAA-835.

[0063] Example 9: Akkermansia myxophilus CCFM1087 promotes quercetin conversion and increases the yield of its active metabolites and their bioavailability in in vitro digestion. Quercetin is a natural flavonol compound widely found in various plant-based foods such as onions, apples, berries, broccoli, tea, and capers, making it one of the most widely distributed and abundant dietary flavonoids in nature. The multiple phenolic hydroxyl groups in the quercetin molecule endow it with extremely strong free radical scavenging and metal ion chelating abilities. Numerous pharmacological studies have shown that quercetin possesses a variety of biological activities, including antioxidant, anti-inflammatory, anti-allergic, antiviral, antitumor, cardiovascular protective, immunomodulatory, and metabolic syndrome improvement activities. Based on these properties, quercetin has been widely developed as a dietary supplement and functional food ingredient, demonstrating significant application value in chronic disease prevention and health promotion. However, due to its poor water solubility and difficulty in effective dissolution in the intestines, quercetin has extremely low oral bioavailability in humans. Bioavailability refers to the degree and speed at which an active ingredient, after entering the body, can be absorbed in its original form or as an active metabolite and reach the systemic circulation or site of action. The absolute oral bioavailability of quercetin in humans is typically only 1%–5%, severely limiting its full efficacy. Therefore, it is necessary to further explore methods to promote the biotransformation of quercetin in the intestine and increase the production level of its active metabolites, in order to improve the intestinal conversion and utilization of quercetin and provide a basis for improving its in vivo bioavailability.

[0064] Fresh feces were added to pre-reduced sterilized modified physiological saline (containing 8.5 g / L NaCl and 0.5 g / L L-cysteine ​​hydrochloride) at a mass-to-volume ratio of 1:10. The mixture was thoroughly homogenized under anaerobic conditions and centrifuged at 1500 rpm for 5 min at 4°C. The supernatant was collected as the fecal microbiota suspension. *Ackermannii myxophilus* CCFM1087 was inoculated into BHI medium containing 0.5 g / L L-cysteine ​​hydrochloride and 2.5 g / L mucin and cultured anaerobicly at 37°C for 48 h. After 2-3 subcultures, the suspension was ready for use. Quercetin was prepared as a 10 mg / mL stock solution using dimethyl sulfoxide and diluted to a final concentration of 100 μg / mL with GMM medium before use.

[0065] A 20 mL fermentation system was constructed in a 100 mL anaerobic Erlenmeyer flask, with the following groups: The CCFM1087 experimental group was supplemented with 16 mL of GMM medium containing 100 μg / mL quercetin, 2 mL of fecal microbiota suspension, and OD... 600 2 mL of Akkermansia citrate CCFM1087 bacterial suspension with an OD value of 1.0, wherein... 600 =1.0 indicates a bacterial culture containing bacterial cells and BHI medium. The fermentation control group (BLK) was prepared by adding 16 mL of GMM medium containing 100 μg / mL quercetin, 2 mL of fecal microbial suspension, and replacing OD with 2 mL of sterile BHI medium. 600 =1.0% Akkermansia xylophilus CCFM1087 bacterial culture. Each group was sealed with a breathable sealing film and placed in an anaerobic workstation at 37℃ for 24 h. After fermentation, the fermentation broth of each group was divided into two portions, 10 mL each. The first portion was used to detect the in vitro conversion rate: 1 mL of the total fermentation broth from each group was taken, and an equal volume of glacial acetonitrile (containing 0.1% formic acid) was added to terminate the reaction. After vortexing, the mixture was centrifuged at 4℃ and 12000 rpm for 10 min. The supernatant was dried under nitrogen, and the residue was reconstituted with 100 μL of 50% methanol, filtered through a 0.22 μm filter, and injected. The concentrations of quercetin and its metabolites protocatechuic acid, 3,4-dihydroxyphenylacetic acid, and isorhamnetin were determined by high performance liquid chromatography-tandem mass spectrometry. Calculate the quercetin conversion rate: Conversion rate (%) = (Amount of initial quercetin - Amount of residual quercetin after fermentation) / Amount of initial quercetin × 100%. Simultaneously calculate the yield of each metabolite: Yield (%) = Total amount of metabolites / Total amount of initial quercetin × 100%. The second part is used for bioavailability determination. In this embodiment, the apparent bioavailability of the active metabolite in an in vitro dialysis model is characterized by its dialyzability. Apparent bioavailability refers to the proportion of the corresponding substance existing in a dialyzable form under the fermentation and dialysis conditions described in this embodiment and possessing potential intestinal absorption capacity. The specific method is as follows: Dialysis treatment of 10 mL of fermentation broth: Add 4 mL of saturated NaHCO3 solution to a cellulose dialysis tube with a molecular weight cutoff of 3 kDa, seal the tube, and completely immerse it in the fermentation broth. Incubate at 37℃ and 100 rpm for 2 h with shaking. Collect the liquid inside the dialysis tube (dialyzable component, denoted as in) and the liquid outside the dialysis tube (undialyzed component, denoted as out). Take 200 μL of each and process them in the same way before injecting to determine the concentration of quercetin and its metabolites. Calculate the dialysability rate based on the concentrations of the samples inside and outside the dialysis tube to simulate the absorption rate: Dialysability rate (%) = (C... in× V in ) / (C in× V in +C out× V outThe dialysability of quercetin precursor and its metabolites was calculated by multiplying the result by 100%. The results are shown in Tables 2 and 3. The main metabolites of quercetin in the intestine are protocatechuic acid, 3,4-dihydroxyphenylacetic acid, and isorhamnetin. After co-incubation with Akkermansia citrate CCFM1087 in a simulated intestinal environment, the conversion rate of quercetin increased by 52.76% compared to the BLK group, and the yields of the metabolites protocatechuic acid, 3,4-dihydroxyphenylacetic acid, and isorhamnetin increased by 46.56%, 52.66%, and 77.84%, respectively. This indicates that Akkermansia citrate CCFM1087 has a synergistic effect with intestinal flora in enhancing the conversion rate of quercetin in the intestine. Further simulation of intestinal absorption using dialysis bags revealed that, compared to the BLK group, the dialysability of the three metabolites protocatechuic acid, 3,4-dihydroxyphenylacetic acid, and isorhamnetin, produced by Akkermansia bacteria CCFM1087 fermentation, increased by 25.94%, 43.56%, and 26.42%, respectively. These results indicate that Akkermansia bacteria CCFM1087 can improve the conversion rate of quercetin by intestinal microorganisms, increase the production of quercetin-related active metabolites, and, moreover, facilitate the existence of these active metabolites in a dialysable form. This significantly improves their apparent dialysability and simulated intestinal absorption potential in the in vitro dialysis model, thereby improving the intestinal conversion and utilization of quercetin and enhancing the apparent bioavailability of its related active metabolites.

[0066] Table 2. Conversion rate of quercetin

[0067] Table 3. Dialyzability of quercetin and its metabolites in in vitro fermentation broth

[0068] Example 10: Akkermansia myxophilus CCFM1087 promotes the conversion of senna-2-glucosinolates and increases the yield of its active metabolites and their bioavailability in in vitro digestion. Fresh fecal samples were collected from six healthy volunteers (3 men and 3 women, who had not consumed alcohol, antibiotics, or probiotics within the past month). Under anaerobic conditions, sterile modified physiological saline containing 8.5 g / L sodium chloride and 0.5 g / L L-cysteine ​​hydrochloride was added at a mass-to-volume ratio of 1:10. After thorough homogenization, the mixture was centrifuged at 1500 r / min for 5 min at 4°C. The supernatant was collected as a fecal microbiota suspension. Equal volumes of the fecal microbiota suspensions from each volunteer were mixed for subsequent in vitro fermentation. *Ackermania maughanii* CCFM1087 was inoculated into BHI liquid medium containing 0.5 g / L L-cysteine ​​hydrochloride and 2.5 g / L mucin and cultured anaerobicly at 37°C for 48 h. After 2-3 generations of activation, the OD of the bacterial suspension was measured. 600Adjusted to 1.0, wherein the OD 600 A bacterial culture with a ratio of 1.0 is a bacterial culture containing CCFM1087 cells and BHI medium.

[0069] An in vitro fermentation system with a total volume of 20 mL was constructed in a 100 mL anaerobic Erlenmeyer flask, setting up a CCFM1087 experimental group and a fermentation control group (BLK). The CCFM1087 experimental group was supplemented with 16 mL of pre-reduced GMM medium containing 100 μg / mL sennapyrin, 2 mL of fecal microbiota suspension, and OD200. 600 =1.0 Akkermansia citrate CCFM1087 bacterial suspension 2 mL; fermentation control group (BLK) added 16 mL of pre-reduced GMM medium containing 100 μg / mL succinate, 2 mL of fecal bacterial suspension, and replaced OD with 2 mL of sterile BHI medium. 600 =1.0 of *Ackermannii myxophilus* CCFM1087 bacterial culture. Each group was sealed with a breathable sealing film and placed in an anaerobic workstation for 24 h at 37℃. After fermentation, the fermentation broth of each group was divided into two portions, 10 mL each. The first portion was used to determine the in vitro conversion rate: 1 mL of the total fermentation broth from each group was taken, and an equal volume of glacial acetonitrile (containing 0.1% formic acid) was added to terminate the reaction. After vortexing, the mixture was centrifuged at 12000 rpm for 10 min at 4℃. The supernatant was dried under nitrogen, and the residue was reconstituted with 100 μL of 50% methanol, filtered through a 0.22 μm filter, and injected. The contents of sennain and its metabolites sennaol-7-O-glucoside, sennaol, and dihydrocaffeic acid were determined by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS). Simultaneously, the conversion rate of senna-2-glucosinolates was calculated: Conversion rate (%) = (Amount of initial senna-2-glucosinolates - Amount of residual senna-2-glucosinolates after fermentation) / Amount of initial senna-2-glucosinolates × 100%. The yield of each metabolite was also calculated: Yield (%) = Total amount of metabolites / Total amount of initial senna-2-glucosinolates × 100%. The second part was used to determine the apparent bioavailability in vitro. In this embodiment, the apparent bioavailability of the active metabolites in an in vitro dialysis model was characterized by their dialyzability. Apparent bioavailability in vitro refers to the proportion of the corresponding substance existing in a dialyzable form under the fermentation and dialysis conditions described in this embodiment and possessing potential intestinal absorption capacity. The specific method is as follows: 10 mL of fermentation broth is dialyzed. 4 mL of saturated NaHCO3 solution is added to a cellulose dialysis tube with a molecular weight cutoff of 3 kDa, and the tube is sealed and completely immersed in the fermentation broth. The tube is incubated at 37℃ and 100 rpm for 2 hours with shaking. The liquid inside the dialysis tube (dialyzable component, denoted as in) and the liquid outside the dialysis tube (undialyzed component, denoted as out) are collected separately. 200 μL of each liquid is processed using the same method and injected to determine the concentration of senna-glucosinolates and their metabolites. The dialysability rate is calculated based on the concentrations of the samples inside and outside the dialysis tube to simulate the absorption rate: Dialysability rate (%) = (C... in ×V in) / (C in ×V in +C out ×V out The dialysability of each metabolite of senna was calculated by multiplying the result by 100%. The results are shown in Table 4. In the BLK control group, the conversion rate of senna was 39.30±3.10%. After adding *Ackermania xylophilus* CCFM1087, the conversion rate of senna increased to 61.90±1.47%, an increase of 57.51% compared to the BLK control group. Meanwhile, in the BLK control group, the molar yields of sennaol-7-O-glucoside, sennaol, and dihydrocaffeic acid were 10.13±0.85%, 15.65±1.20%, and 5.91±0.95%, respectively. In the CCFM1087 group, the molar yields of the above three metabolites increased to 16.28±1.35%, 26.67±2.51%, and 10.01±1.86%, respectively. Compared with the BLK control group, the molar yields of semperflorens-7-O-glucoside, semperflorens, and dihydrocaffeic acid in the CCFM1087 group increased by 60.71%, 70.42%, and 69.37%, respectively. The total molar yield of the three detected metabolites increased from 31.69% in the BLK control group to 52.96% in the CCFM1087 group, an increase of 67.12%. Further dialysis was used to simulate intestinal absorption, and the results are shown in Table 5. In the BLK control group, the dialysability of semperflorens-7-O-glucoside, semperflorens, and dihydrocaffeic acid were 24.36±1.30%, 15.63±0.95%, and 16.20±1.75%, respectively. After the addition of *Akkermansia myxophilus* CCFM1087, the dialysability of the three metabolites increased to 36.25±0.99%, 26.39±1.22%, and 27.12±1.19%, respectively. Compared with the BLK control group, the dialysability of sucralose-7-O-glucoside, sucralose, and dihydrocaffeic acid in the CCFM1087 group increased by 48.81%, 68.84%, and 67.41%, respectively. Among them, the dialysability of sucralose and dihydrocaffeic acid, the important active metabolites of sucralose, showed the most significant increases. These results indicate that *Akkermansia myxophilus* CCFM1087 can promote the conversion of sucralose mediated by human intestinal microorganisms and increase the production of bioactive metabolites such as sucralose-7-O-glucoside, sucralose, and dihydrocaffeic acid. Meanwhile, CCFM1087 fermentation facilitates the presence of the above-mentioned active metabolites in a dialyzable form, significantly improving their apparent dialyzability and simulated intestinal absorption potential in the in vitro dialysis model, thereby improving the intestinal conversion and utilization of senna-glucosinolates and enhancing the apparent bioavailability of its related active metabolites in vitro.

[0070] Table 4. Conversion rate of sucralose in in vitro fermentation system

[0071] Table 5. Dialyzability of active metabolites of senna-2-glucosinolates in the in vitro fermentation system

[0072] Example 11: Inhibitory effect of Akkermansia CCFM1087 on lipase activity Lipase is a key enzyme in the body that breaks down dietary fat into free fatty acids and glycerol, and its activity directly affects the efficiency of fat absorption in the intestines. By inhibiting lipase activity, the hydrolysis and absorption of dietary fat can be reduced, thereby decreasing the body's fat intake, reducing energy accumulation, and achieving the goals of weight control, improving obesity and related metabolic disorders.

[0073] Fresh fecal samples were collected from six healthy volunteers (3 men and 3 women, who had not consumed alcohol, antibiotics, or probiotics in the past month). The fresh fecal samples were added to pre-reduced sterilized modified physiological saline (containing 8.5 g / L NaCl and 0.5 g / L L-cysteine ​​hydrochloride) at a mass-to-volume ratio of 1:10. The mixture was thoroughly homogenized under anaerobic conditions and centrifuged at 1500 rpm for 5 min at 4°C. The supernatant was collected as the fecal microbiota suspension. *Ackermannii myxophilus* CCFM1087 was inoculated into BHI medium containing 0.5 g / L L-cysteine ​​hydrochloride and 2.5 g / L mucin and cultured anaerobicly at 37°C for 48 h. The culture was then passaged three times before use.

[0074] A 10 mL fermentation system was constructed in 15 mL centrifuge tubes, and three experimental groups were set up: a fermentation control group, an ATCC BAA-835 experimental group, and an Akkermansia xylophilus CCFM1087 experimental group. The fermentation systems of each experimental group are shown in Table 6. The BAA-835 and CCFM1087 bacterial suspensions mentioned in the table were resuspended in sterile physiological saline and the OD was adjusted. 600 The bacterial culture was increased to 1.0. Each experimental group was sealed and anaerobically cultured at 37℃ for 24 h. After fermentation, each fermentation broth was centrifuged at 4℃ and 4000 rpm / min for 15 min, and the fermentation supernatant was collected for lipase activity inhibition experiments. The lipase activity inhibition experiment used the p-nitrophenyl palmitate (p-NPP) method. The experimental setup and treatment methods for each group in the lipase activity inhibition experiment are shown in Table 7. The substrate mentioned in the table is p-NPP, and the fermentation supernatant mentioned in the table is the fermentation supernatant of the fermentation system in Table 7. After mixing the additives of each group evenly, the mixture was incubated at 37℃ for 30 min, and the absorbance value was measured at a wavelength of 405 nm. Inhibition rate (%) = [1 - (OD200) / (1 - 0.05 ... 发酵实验组 -OD 实验背景组 ) / (OD 酶活性对照组 -OD 空白对照组 The experiment was conducted with 3 replicates, and the results are expressed as mean ± standard deviation. The results are as follows: Figure 9 As shown, the inhibition rate of lipase activity in the fermentation control group was 23.27±3.06%, the inhibition rate of lipase activity by the Akkermansia standard strain ATCC BAA-835 was 25.57±2.92%, and the inhibition rate of lipase activity by Akkermansia CCFM1087 was 41.23±2.33%. Compared with the fermentation control group, the inhibition rate of lipase activity by Akkermansia CCFM1087 was increased by 77.14%, while the Akkermansia standard strain ATCC BAA-835 did not significantly increase the inhibitory effect on lipase activity. Compared with the standard strain BAA-835, the inhibitory effect of Akkermansia CCFM1087 on lipase activity was increased by 69.30%, indicating that CCFM1087 has a certain inhibitory effect on lipase activity.

[0075] Table 6. In vitro fermentation systems for each experimental group

[0076] Table 7. Experimental Grouping for Lipase Activity Inhibition

[0077] Example 12: Akkermansia CCFM1087 used to prepare a bacterial powder for alleviating obesity. Akkermansia CCFM1087 can be used to prepare bacterial powder. The specific preparation process for the bacterial powder is as follows: Single colonies of *Akkermansia* CCFM1087 obtained in Example 1 were picked and inoculated into food-grade liquid culture medium. The composition of each liter of this medium was: 10.0 g soybean peptone, 5.0 g yeast extract, 5.0 g glucose, 5.0 g sodium chloride, 2.0 g dipotassium hydrogen phosphate, and 0.1 g L-cysteine ​​hydrochloride. The pH was adjusted to 7.4 ± 0.2. The inoculated medium was then cultured in an anaerobic incubator at 37°C for 48 h to obtain an activated solution. This activated solution was then inoculated into the same composition of food-grade liquid culture medium at a 3% (v / v) inoculation rate and cultured in an anaerobic incubator at 37°C for 48 h to obtain a primary seed culture. The primary seed culture was then inoculated into the same composition of food-grade liquid culture medium at a 3% (v / v) inoculation rate and cultured in an anaerobic incubator at 37°C for 48 h to obtain a secondary seed culture. The secondary seed culture was then inoculated into the same composition of food-grade liquid culture medium at a 3% (v / v) inoculation rate and cultured in an anaerobic incubator at 37°C for 48 h to obtain a secondary seed culture. h, to obtain bacterial culture; centrifuge the bacterial culture at 8000 g for 15 min, collect the precipitate, wash the precipitate twice with sterile physiological saline, and then centrifuge at 8000 g for 10 min to obtain bacterial cells; resuspend the Akkermansia bacteria in a protective solution containing 130 g / L skim milk, 20 g / L trehalose and 20 g / L sucrose to a bacterial concentration of 5 × 10⁻⁶. 9CFU / mL; freeze-dry the resuspended bacterial solution to obtain Akkermania CCFM1087 bacterial powder.

[0078] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.

Claims

1. Akkermansia ( Akkermansia muciniphila CCFM1087, characterized in that, It was deposited at the Guangdong Provincial Center for Microbial Culture Collection on February 4, 2026, with accession number GDMCC No: 67807.

2. The metageneric agent of Akkermansia CCFM1087 as described in claim 1.

3. The epigenetic agent according to claim 2, characterized in that, Includes inactivated cells of Akkermansia CCFM1087, metabolites of Akkermansia CCFM1087, and / or lysate components of Akkermansia CCFM1087.

4. A composition, characterized in that, It includes Akkermansia CCFM1087 as described in claim 1 and / or the metagene as described in any of claims 2 to 3.

5. The composition according to claim 4, characterized in that, The composition is a food, health product, or drug.

6. The composition according to claim 4 or 5, characterized in that, It also contains quercetin and / or rutin.

7. The use of Akkermansia citrate CCFM1087 as described in claim 1 and / or the metabiotic as described in any one of claims 2 to 3 in the preparation of a medicament for the prevention and / or treatment of obesity-related metabolic disorders.

8. The use of Akkermansia CCFM1087 as described in claim 1 and / or the metabiotic as described in any one of claims 2 to 3 in the preparation of products for reducing body weight, reducing fat accumulation and / or inhibiting lipase activity.

9. The use of Akkermansia CCFM1087 as described in claim 1 and / or the metabiotic as described in any one of claims 2 to 3 in the preparation of a medicine or health product that helps regulate the intestinal flora.

10. The use of Akkermansia CCFM1087 as described in claim 1 in the preparation of products for promoting the intestinal conversion of quercetin and / or senna-2-glucosinolates and / or improving the bioavailability of their active metabolites.

Images